Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'

Published 23/05/2024, 13:30
© Reuters.  Walmart, Vertex Pharmaceuticals And More On CNBC\'s \'Final Trades\'
VRTX
-
WMT
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Joseph M. Terranova of Virtus Investment Partners named VanEck Semiconductor ETF (NASDAQ:SMH) on CNBC's “Halftime Report Final Trades.”

If NVIDIA Corporation (NASDAQ:NVDA) goes above the $1,000 level, Terranova recommends buying puts on the SMH.

Jason Snipe of Odyssey Capital Advisors said he likes Walmart Inc. (NYSE:WMT). The company reported a “really strong” quarter, with e-commerce sales surging 21%.

Don't forget to check out our premarket coverage here

On May 16, Walmart announced first-quarter 2025 results with strong growth in revenue and operating income.

The retailer reported that in the first quarter of 2025, the adjusted EPS was 60 cents, beating the consensus of 52 cents. Sales were $161.51 billion, up 6.0% year over year or 5.8% (at constant currency), including a benefit of ~1% from an additional selling day, beating the consensus of $159.50 billion.

Jim Lebenthal of Cerity Partners said Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) hit an all-time high on Wednesday and will go higher from here.

On May 6, Vertex Pharmaceuticals posted stronger-than-expected results for its first quarter. The company reported quarterly adjusted earnings of $4.76 per share, beating market estimates of $4.06 per share. Sales came in at $2.69 billion topping expectations of $2.579 billion.

Price Action:

  • Walmart shares rose 0.2% to close at $65.25 on Wednesday.
  • VanEck Semiconductor ETF gained 0.8% during Wednesday's session.
  • Vertex Pharmaceuticals shares gained 1.3% to close at $447.53 during Wednesday's session.
Check This Out: Top 5 Industrials Stocks That May Explode This Quarter

Image: Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.